Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

AVEO's Tivozanib Demonstrates Anti-Tumor Activity In Engineered Lung Tumors Exhibiting Treatment Resistant Mutations
AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced data which demonstrates that tivozanib (AV-951) - the company"s oral, triple VEGF receptor inhibitor - exhibits potent anti-angiogenic and anti-tumor activity in AVEO"s proprietary in vivo lung cancer models. Specifically, treatment with tivozanib resulted in complete tumor growth inhibition or tumor regression (shrinkage) in lung tumors driven by EGFR or KRAS mutations, which are especially difficult to treat. These data are being presented today at the 13th World Conference on Lung Cancer (WCLC) in San Francisco, abstract number PD10.1.5.
generic viagra online
AVEO's Tivozanib Demonstrates Anti-Tumor Activity In Engineered Lung Tumors Exhibiting Treatment Resistant Mutations
AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced data which demonstrates that tivozanib (AV-951) - the company"s oral, triple VEGF receptor inhibitor - exhibits potent anti-angiogenic and anti-tumor activity in AVEO"s proprietary in vivo lung cancer models. Specifically, treatment with tivozanib resulted in complete tumor growth inhibition or tumor regression (shrinkage) in lung tumors driven by EGFR or KRAS mutations, which are especially difficult to treat. These data are being presented today at the 13th World Conference on Lung Cancer (WCLC) in San Francisco, abstract number PD10.1.5.
News of the day
The 90-Year Evolution Of Swine Flu
The current H1N1 swine flu strain has genetic roots in an illness that sickened pigs at the 1918 Cedar Rapids Swine Show in Iowa, report infectious disease experts at the University of Pittsburgh Graduate School of Public Health in the New England Journal of Medicine. Their paper, published online and slated for the July 16 print issue, describes H1N1"s nearly century-long and often convoluted journey, which may include the accidental resurrection of an extinct strain.
Diagnostics

Independent Study Confirms Superior Properties Of ZPC(TM) Enhanced Calcium Composite Bone Grafts

A recent independent study has confirmed Fortoss Vital(R), developed by the Pioneering Orthobiologics Company, Biocomposites, as an effective bone replacement material demonstrating superior bone regenerative properties due to its unique negative zeta potential control (ZPC(TM)). The research carried out by the hospital and departments of the university of Aachen and the Universities of Munich and Regensburg, Germany, analysed the osteogenic potential of Fortoss Vital for maxillary sinus floor augmentation on a 61 year old female. The samples taken from the graft site at 6 months, showed the negative surface charge of Fortoss Vital had accelerated the bone formation cascade and rapidly produced mature lamellar bone formation with marrow cavities. The bone density at the graft site was shown to be denser than the original bone matrix of the posterior maxillary region. Evidence also confirmed the complete resorption of Fortoss Vital. Fortoss Vital is a unique, bi-phasic calcium composite bone graft material having a negative surface charge which attracts the key proteins and cells for rapid osteogenesis and bone repair. Fortoss Vital is fully resorbed by osteoclastic processes and replaced by bone. Biocomposites" Managing Director Stephen Bratt said, "This independent clinical data in a maxillofacial indication, corroborates similar orthopaedic studies confirming that Biocomposites" ZPC technology, with a unique surface chemistry accelerates bone growth. About the company: Biocomposites is a privately held, leading developer, manufacturer and distributor of synthetic, tissue regeneration products. Since 1997, the company has developed a broad range of products that addresses the clinical and economic needs of medical specialties in orthopaedics and dentistry. Research, manufacturing, sales and marketing are directed from the company"s headquarters in Keele, Staffordshire, UK. Biocomposites also has two subsidiary companies, based in Shanghai, P.R.China and Wilmington, North Carolina, USA. Fortoss Vital(R) and Biocomposites(R) The Next Regeneration(TM) are registered trademarks of Biocomposites Ltd. Referenes: Smeets et al. " A new biphasic osteoinductive calcium composite material with a negative Zeta potential for bone augmentation." Head & face Medicine 2009, 5:13 doi:10.1186/1746-160X-5-13. Biocomposites Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009